X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ADCOCK INGRAM (S. Africa) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   ADCOCK INGRAM
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
ADCOCK INGRAM
Jun-14
DR. REDDYS LAB/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs2,788342-   
Low Rs1,902247-   
Sales per share (Unadj.) Rs860.8101.8-  
Earnings per share (Unadj.) Rs57.1-25.6-  
Cash flow per share (Unadj.) Rs122.0-21.3-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.779.9-  
Shares outstanding (eoy) m165.91168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.72.9 94.2%   
Avg P/E ratio x41.1-11.5 -357.8%  
P/CF ratio (eoy) x19.2-13.9 -138.7%  
Price / Book Value ratio x3.13.7 83.9%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,03449,710 782.6%   
No. of employees `00023.54.3 548.0%   
Total wages/salary Rs m32,1493,120 1,030.4%   
Avg. sales/employee Rs Th6,070.84,002.0 151.7%   
Avg. wages/employee Rs Th1,366.6726.7 188.1%   
Avg. net profit/employee Rs Th402.5-1,008.4 -39.9%   
INCOME DATA
Net Sales Rs m142,81017,181 831.2%  
Other income Rs m1,552120 1,290.0%   
Total revenues Rs m144,36217,301 834.4%   
Gross profit Rs m23,512-2,977 -789.7%  
Depreciation Rs m10,772742 1,452.7%   
Interest Rs m788465 169.3%   
Profit before tax Rs m13,504-4,064 -332.3%   
Minority Interest Rs m0-11 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380254 1,724.8%   
Profit after tax Rs m9,468-4,329 -218.7%  
Gross profit margin %16.5-17.3 -95.0%  
Effective tax rate %32.4-6.2 -519.1%   
Net profit margin %6.6-25.2 -26.3%  
BALANCE SHEET DATA
Current assets Rs m104,98412,584 834.3%   
Current liabilities Rs m68,9387,080 973.7%   
Net working cap to sales %25.232.0 78.8%  
Current ratio x1.51.8 85.7%  
Inventory Days Days74111 67.0%  
Debtors Days Days104124 83.6%  
Net fixed assets Rs m104,3857,335 1,423.1%   
Share capital Rs m83080 1,040.5%   
"Free" reserves Rs m124,8860-   
Net worth Rs m125,71613,485 932.3%   
Long term debt Rs m25,0894,739 529.4%   
Total assets Rs m225,44325,474 885.0%  
Interest coverage x18.1-7.7 -234.6%   
Debt to equity ratio x0.20.4 56.8%  
Sales to assets ratio x0.60.7 93.9%   
Return on assets %4.5-15.2 -30.0%  
Return on equity %7.5-32.1 -23.5%  
Return on capital %9.7-19.8 -49.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m53,7070-   
CASH FLOW
From Operations Rs m18,0301,467 1,229.5%  
From Investments Rs m-14,883-450 3,305.2%  
From Financial Activity Rs m-4,4404,301 -103.2%  
Net Cashflow Rs m-1,2365,317 -23.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.72 Rs / ZAR

Compare DR. REDDYS LAB With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: SANOFI INDIA  DISHMAN PHARMA  ALKEM LABORATORIES  FULFORD INDIA  PIRAMAL ENTERPRISES  



Today's Market

Nifty Hits Fresh Record High; Sensex Up Over 330 Points(12:30 pm)

After opening the day on a positive note, stock markets in India continued their momentum and went on to scale their record-high levels.

Related Views On News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 20, 2018 03:37 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - ALEMBIC LTD COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS